[go: up one dir, main page]

WO2009038107A1 - Combined pharmaceutical preparation for treatment of type-2 diabetes - Google Patents

Combined pharmaceutical preparation for treatment of type-2 diabetes Download PDF

Info

Publication number
WO2009038107A1
WO2009038107A1 PCT/JP2008/066809 JP2008066809W WO2009038107A1 WO 2009038107 A1 WO2009038107 A1 WO 2009038107A1 JP 2008066809 W JP2008066809 W JP 2008066809W WO 2009038107 A1 WO2009038107 A1 WO 2009038107A1
Authority
WO
WIPO (PCT)
Prior art keywords
acceptable salt
pharmacologically acceptable
diabetes
type
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/066809
Other languages
French (fr)
Japanese (ja)
Inventor
Mitsutaka Shimasaki
Naoki Kobayashi
Tatsuro Takei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd, Takeda Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Priority to JP2009533167A priority Critical patent/JPWO2009038107A1/en
Publication of WO2009038107A1 publication Critical patent/WO2009038107A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a pharmaceutical preparation comprising a combination of mitiglinide (which is a substance useful for the treatment of type-2 diabetes) or a pharmacologically acceptable salt thereof and pioglitazone or a pharmacologically acceptable salt thereof. Also disclosed is a combined pharmaceutical preparation in which the therapeutic effect of pioglitazone or a pharmacologically acceptable salt thereof on type-2 diabetes can be enhanced in a patient in whom the blood glucose level cannot be sufficiently controlled by the administration of pioglitazone or the pharmacologically acceptable salt thereof alone, and in which the adverse side effects caused by the components contained therein cannot be increased synergistically. Thus, specifically disclosed is a pharmaceutical preparation for the treatment of type-2 diabetes, which comprises a combination of mitiglinide of the formula (Ia) or a pharmacologically acceptable salt thereof and pioglitazone of the formula (IIa) or a pharmacologically acceptable salt thereof.
PCT/JP2008/066809 2007-09-21 2008-09-18 Combined pharmaceutical preparation for treatment of type-2 diabetes Ceased WO2009038107A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009533167A JPWO2009038107A1 (en) 2007-09-21 2008-09-18 Combination medicine for type 2 diabetes treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007245437 2007-09-21
JP2007-245437 2007-09-21

Publications (1)

Publication Number Publication Date
WO2009038107A1 true WO2009038107A1 (en) 2009-03-26

Family

ID=40467917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/066809 Ceased WO2009038107A1 (en) 2007-09-21 2008-09-18 Combined pharmaceutical preparation for treatment of type-2 diabetes

Country Status (2)

Country Link
JP (1) JPWO2009038107A1 (en)
WO (1) WO2009038107A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1817347A (en) * 2006-03-10 2006-08-16 北京阜康仁生物制药科技有限公司 Medicinal composition with miglinon and proactidil as active components, and preparing method and use thereof
WO2008026668A1 (en) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Medicinal composition containing insulin resistance improving agent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1817347A (en) * 2006-03-10 2006-08-16 北京阜康仁生物制药科技有限公司 Medicinal composition with miglinon and proactidil as active components, and preparing method and use thereof
WO2008026668A1 (en) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Medicinal composition containing insulin resistance improving agent

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EIJI KUDO: "Insulin Chusha kara Mitiglinide eno Kirikae no Kanosei", PHARMA MEDICA, vol. 24, no. 6, 10 June 2006 (2006-06-10), pages 125 - 132 *
MASATOSHI KIKUCHI ET AL.: "Sokkosei·Tanjikan Sayogata Insulin Bunpitsu Sokushin'yaku Mitiglinide to Insulin Teikosei Kaizen'yaku Pioglitazone no Heiyo Ryoho no Yuyosei", THE JOURNAL OF THE JAPAN DIABETIC SOCIETY, vol. 51, no. 1, 25 April 2008 (2008-04-25), pages S-184 *
MASAZUMI FUJIWARA: "SU-yaku kara Mitiglinide eno Kirikae ni yori HbAlC ga Yui ni Teika shita 2-gata Tonyobyo Shorei no Kento", PROGRESS IN MEDICINE, vol. 28, no. 6, 10 June 2008 (2008-06-10), pages 1541 - 1545 *
RYO MORIKAWA ET AL.: "Tandoku o Gappei shita Michiryo 2-gata Tonyobyo no 1-rei", THE JOURNAL OF THE JAPAN DIABETIC SOCIETY, vol. 50, no. 3, 30 March 2007 (2007-03-30), pages 224 *
SHOICHI HATAKE ET AL.: "Mitiglinide ni yoru To Fukago no Ketto Koka Sayo ni Taisuru Pioglitazone Choki Toyo no Koka -OLETF Rat o Mochiita Kento", THE JOURNAL OF THE JAPAN DIABETIC SOCIETY, vol. 51, no. 1, 25 April 2008 (2008-04-25), pages S-285 *
SHOICHI HATAKE ET AL.: "Pioglitazone nite Chiryochu no 2-gata Tonyobyo Kanja ni Okeru Mitiglinide Heiyo Koka no Kento -Teiyoryo SU-yaku Heiyo Koka tono Hikaku", THE JOURNAL OF THE JAPAN DIABETIC SOCIETY, vol. 49, no. 1, 25 April 2006 (2006-04-25), pages S-129 *

Also Published As

Publication number Publication date
JPWO2009038107A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
EA200800198A1 (en) METHODS OF PREVENTION AND TREATMENT OF METABOLIC DISORDERS AND NEW DERIVATIVES OF PYRAZOL-O-GLYCOSIDE
WO2006031856A3 (en) Biosynchronous transdermal drug delivery
WO2005105213A3 (en) Indole and azaindole derivatives with antitumor action
NO2014028I2 (en) Glucopyranosyl-substituted benzene derivatives, process for their preparation, physiologically acceptable salts of such compounds, drugs containing such compounds and combinations with other active substances, and their use in the manufacture of drugs for the treatment of disease
EP2371853A3 (en) Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
WO2007098479A3 (en) Localized insulin delivery for bone healing
EA200501420A1 (en) DELIVERY DEVICE FOR DRUG AND CELL THERAPY
EA200900896A1 (en) HETEROCYCLIC COMPOUND RECEPTOR-AGONISTS (VARIANTS) PHARMACEUTICAL COMPOSITION ON THEIR BASIS METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS, a method of stimulating insulin production (VARIANTS) AND METHODS FOR REDUCING GLUCOSE LEVEL IN BLOOD AND TRIGLYCERIDES BY COMPOUNDS LISTED
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
NO20083863L (en) Pyrazoles such as 11-beta-hsd-1
CL2007002347A1 (en) COMPOUNDS DERIVED FROM PHENYLL, PYRIDINE AND QUINOLINE; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF MELLITUS DIABETES, DISORDERS IN THE TOLERANCE OF GLUCOSE, OBESITY, CROHN'S DISEASE, SICK
WO2009127974A3 (en) Pharmaceutical formulation for treating cardiovascular disease
WO2010042471A3 (en) Medical devices for delivery of therapeutic agents to body lumens
MX336657B (en) Prevention of hypoglycaemia in diabetes mellitus type 2 patients.
TN2009000317A1 (en) Solid preparation comprising alogliptin and pioglitazone
WO2007128817A3 (en) Insulin derivative
WO2010015849A3 (en) Pyrazolo [3,4] pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity
EP2216024A3 (en) Use of Ranolazine for the treatment of cardiovascular diseases
WO2010005980A8 (en) Tacrolimus for improved treatment of transplant patients
WO2008149802A1 (en) Anti-fatigue agent and oral composition each comprising andrographolide as active ingredient
TW200604193A (en) Substituted oxazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
MX2009011900A (en) Diabetic wound healing.
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
EA201100916A1 (en) COMBINATION OF INSULIN WITH TRIAZINE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF DIABETES
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08831697

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009533167

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08831697

Country of ref document: EP

Kind code of ref document: A1